Page last updated: 2024-08-25

3-deazaneplanocin and Osteogenic Sarcoma

3-deazaneplanocin has been researched along with Osteogenic Sarcoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C	1

Other Studies

1 other study(ies) available for 3-deazaneplanocin and Osteogenic Sarcoma

Article	Year
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. Anti-cancer drugs, 2016, Volume: 27, Issue:10 Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Osteosarcoma; Vorinostat	2016

Article

Year

Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.

Anti-cancer drugs, 2016, Volume: 27, Issue:10

Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Osteosarcoma; Vorinostat

2016